+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07699328

Evaluation of VRN110755 Safety and Effectiveness in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

Led by Voronoi, Inc · Updated on 2026-11-03

315

Participants Needed

29

Research Sites

39 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating VRN110755, an investigational oral drug that selectively targets the epidermal growth factor receptor EGFR mutations in patients with EGFR-mutant non-small cell lung cancer NSCLC. This Phase 12, open-label study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor effects of VRN110755, including in patients who have developed resistance to prior EGFR tyrosine kinase inhibitor therapies. The study includes dose-escalation, dose-expansion, and further evaluation phases to determine appropriate dosing and preliminary efficacy. Participants receive VRN110755 orally once daily in 28-day treatment cycles. The study begins with a Phase 1a dose-escalation to identify the maximum tolerated dose, followed by a Phase 1b dose-expansion across specific molecularly defined EGFR-mutant NSCLC groups to find the recommended Phase 2 dose. Selected groups continue into Phase 2 to further evaluate the drugs effects. Treatment continues until disease progression, unacceptable side effects, withdrawal, new anticancer therapy, death, or study completion. During the study, participants undergo regular assessments including monitoring of side effects, vital signs, laboratory tests, physical and eye exams, electrocardiograms, and performance status evaluations. Researchers also measure drug levels in the blood and tumor DNA changes, as well as clinical outcomes such as tumor response, disease control, progression-free survival, and overall survival. Follow-up may continue for up to six years to track long-term safety and treatment effects.

CONDITIONS

Brief Title

A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

Research Team

T

Trial Information

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here